share_log

Vivos Therapeutics | 8-K: Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics | 8-K: Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics | 8-K:Vivos Therapeutics公布2024年第二季度财务业绩并提供最新运营情况
美股SEC公告 ·  08/15 12:57
Moomoo AI 已提取核心信息
On August 14, 2024, Vivos Therapeutics, Inc., a medical device and technology company specializing in treatments for sleep-related breathing disorders, announced its financial results for the second quarter ended June 30, 2024. The company reported a 19% increase in revenue to $4.1 million for the quarter and $7.5 million for the first half of the year. This growth is attributed to higher product sales and service revenue, including an increase in Vivos Integrated Provider enrollment revenue. Gross profit also rose to $2.7 million for the quarter, with a gross margin increase to 65%. Operating expenses decreased by 31% due to successful cost-cutting initiatives, leading to a significant reduction in operating loss. Vivos also highlighted its strategic marketing and distribution alliance with a Colorado sleep treatment operator and a...Show More
On August 14, 2024, Vivos Therapeutics, Inc., a medical device and technology company specializing in treatments for sleep-related breathing disorders, announced its financial results for the second quarter ended June 30, 2024. The company reported a 19% increase in revenue to $4.1 million for the quarter and $7.5 million for the first half of the year. This growth is attributed to higher product sales and service revenue, including an increase in Vivos Integrated Provider enrollment revenue. Gross profit also rose to $2.7 million for the quarter, with a gross margin increase to 65%. Operating expenses decreased by 31% due to successful cost-cutting initiatives, leading to a significant reduction in operating loss. Vivos also highlighted its strategic marketing and distribution alliance with a Colorado sleep treatment operator and a $7.5 million equity investment from New Seneca Partners, Inc. The company anticipates positive cash flow in early 2025 and has treated over 45,000 patients with its patented oral appliances. Additionally, Vivos received regulatory approvals for Medicare reimbursement for its CARE oral devices and announced positive results from a marketing pilot for its oral appliance therapy.
2024年8月14日,专门治疗睡眠呼吸障碍的医疗器械和科技公司Vivos Therapeutics, Inc.宣布了截至2024年6月30日的第二季度财务业绩。该公司报告称,本季度营业收入增长19%至410万美元,全年上半年收入为750万美元。这一增长归因于更高的产品销售和服务收入,包括Vivos综合服务供应商招募收入的增长。毛利润也在本季度增长至270万美元,毛利率增长到65%。由于成本削减方案的成功,营业费用下降了31%,从而大幅减少了营业亏损。Vivos还强调了与科罗拉多州的一个睡眠治疗运营商的战略营销和分销联盟以及来自New Seneca Partners, Inc.的750万美元股本投资。该公司预计在2025年初实现现金流的正数,并已为超过45,000名患者提供了其专利口腔设备的治疗。此外,Vivos已获得其CARE口腔设备的医疗保险报销的监管批准,并宣布其口腔设备疗法的营销试点取得了积极的成果。
2024年8月14日,专门治疗睡眠呼吸障碍的医疗器械和科技公司Vivos Therapeutics, Inc.宣布了截至2024年6月30日的第二季度财务业绩。该公司报告称,本季度营业收入增长19%至410万美元,全年上半年收入为750万美元。这一增长归因于更高的产品销售和服务收入,包括Vivos综合服务供应商招募收入的增长。毛利润也在本季度增长至270万美元,毛利率增长到65%。由于成本削减方案的成功,营业费用下降了31%,从而大幅减少了营业亏损。Vivos还强调了与科罗拉多州的一个睡眠治疗运营商的战略营销和分销联盟以及来自New Seneca Partners, Inc.的750万美元股本投资。该公司预计在2025年初实现现金流的正数,并已为超过45,000名患者提供了其专利口腔设备的治疗。此外,Vivos已获得其CARE口腔设备的医疗保险报销的监管批准,并宣布其口腔设备疗法的营销试点取得了积极的成果。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息